Jessica Mendoza

Pretty soon, the Novo Nordisk Foundation, the nonprofit running Novo Nordisk the company, started to have concerns over their ability to keep pace with Eli Lilly. And in January, those fears became a reality. New data showed that U.S. prescriptions for Lilly's Zepbound had beaten Novo's Wegovi for the first time.

And so, after eight years of leading Novo and helping it become one of the most profitable drug makers in the world, Jørgensen's time was up. Last Friday, the company announced that the CEO was leaving.

And so, after eight years of leading Novo and helping it become one of the most profitable drug makers in the world, Jørgensen's time was up. Last Friday, the company announced that the CEO was leaving.

And so, after eight years of leading Novo and helping it become one of the most profitable drug makers in the world, Jørgensen's time was up. Last Friday, the company announced that the CEO was leaving.

Has Jørgensen himself said anything about the decision?

Has Jørgensen himself said anything about the decision?

Has Jørgensen himself said anything about the decision?

After the announcement, Novo employees gathered to cheer on their departing boss as he descended a winding staircase at the company's headquarters. With Juergensen headed for the exit, the company announced it would bring back someone with deep institutional knowledge, a previous CEO.

After the announcement, Novo employees gathered to cheer on their departing boss as he descended a winding staircase at the company's headquarters. With Juergensen headed for the exit, the company announced it would bring back someone with deep institutional knowledge, a previous CEO.

After the announcement, Novo employees gathered to cheer on their departing boss as he descended a winding staircase at the company's headquarters. With Juergensen headed for the exit, the company announced it would bring back someone with deep institutional knowledge, a previous CEO.

The old Lars, Lars Sorensen, was actually Lars Jørgensen's predecessor. Sorensen was CEO at the time when Novo was just beginning to set the stage for its GLP-1 success. Now, he'll be returning to oversee the company's future.

The old Lars, Lars Sorensen, was actually Lars Jørgensen's predecessor. Sorensen was CEO at the time when Novo was just beginning to set the stage for its GLP-1 success. Now, he'll be returning to oversee the company's future.

The old Lars, Lars Sorensen, was actually Lars Jørgensen's predecessor. Sorensen was CEO at the time when Novo was just beginning to set the stage for its GLP-1 success. Now, he'll be returning to oversee the company's future.

Novo Nordisk says it won't be changing its strategy, despite the shakeups at the top. Thank you.

Novo Nordisk says it won't be changing its strategy, despite the shakeups at the top. Thank you.

Novo Nordisk says it won't be changing its strategy, despite the shakeups at the top. Thank you.

Well, thank you for being here and being so patient with all of our tech stuff. Last year, I interviewed Lars Sorensen, the returning Lars, for our series Trillion Dollar Shot, which is about the rise of GLP-1 drugs. At the time, I asked him about Novo's rivalry with Eli Lilly. Who would you say is winning the competition right now?

Well, thank you for being here and being so patient with all of our tech stuff. Last year, I interviewed Lars Sorensen, the returning Lars, for our series Trillion Dollar Shot, which is about the rise of GLP-1 drugs. At the time, I asked him about Novo's rivalry with Eli Lilly. Who would you say is winning the competition right now?

Well, thank you for being here and being so patient with all of our tech stuff. Last year, I interviewed Lars Sorensen, the returning Lars, for our series Trillion Dollar Shot, which is about the rise of GLP-1 drugs. At the time, I asked him about Novo's rivalry with Eli Lilly. Who would you say is winning the competition right now?

Sorensen told me he had the highest respect for Eli Lilly and that they keep each other on their toes.